FORCYTE BIOTECHNOLOGIES, INC.

Los Angeles, CA · Founded 2017 · CIK 0001760069 · Medtech · Private

integrated in vitro cardiac contractility assay platform with embedded electrical pacing system for high-throughput drug screening and patient-specific cardiotoxicity testing

forcytebio.com →
Grants
$4.1M
11 awards
Sector median: 1
Raised
$1.0M
1 Form D · Jan 2019
93 months since last filing
Contracts
—
No federal contracts on record
Patents
5
0 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Multiplexed single-cell contractility assay to develop therapeutics for asthma and hypertension$224,987
Federal grantDepartment of Health and Human Services · Phase I · High-throughput screening of vasoprotectors in the brain using single-cell force mapping towards anti-migraine therapies$224,905
Federal grantDepartment of Health and Human Services · Phase I · High-throughput screening of uterine smooth muscle contractility towards therapies to prevent pre-term birth$224,997
Federal grantDepartment of Health and Human Services · Phase I · High-throughput screening of vasoprotectors in the brain using single-cell force mapping towards anti-migraine therapies$41,583
Private capital raisedForm D · SEC$1,000,000
Federal grantDepartment of Health and Human Services · Phase I · High-throughput screening of vasoprotectors in the brain using single-cell force mapping towards anti-migraine therapies$21,543
Federal grantDepartment of Health and Human Services · Phase II · Functional high-throughput contractility assay suite to develop therapeutics for asthma andhypertension$1,703,531
Federal grantDepartment of Health and Human Services · Phase II · Functional high-throughput contractility assay suite to develop therapeutics for asthma andhypertension$66,248
Federal grantDepartment of Health and Human Services · Phase II · Functional high-throughput contractility assay suite to develop therapeutics for asthma andhypertension$810,473
Federal grantDepartment of Health and Human Services · Phase I · Small molecule enhancers of detrusor contraction discovered using a functional cell contractility screen as therapeutic candidates for underactive bladder$352,511
Federal grantDepartment of Health and Human Services · Phase I · Smart, integrated well-plates for ultra-high-throughput screening of excitation-contraction coupling in tissues$350,000
Federal grantDepartment of Health and Human Services · Phase I · Small molecule enhancers of detrusor contraction discovered using a functional cell contractility screen as therapeutic candidates for underactive bladder$41,550
Federal grant · SBIR/STTRForm D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1103AGILE DEVICES, INC.—$4.4M
1104PICCOLO MEDICAL, INC.—$3.3M
1105Everygene, PBC—$7.4M
1106FORCYTE BIOTECHNOLOGIES, INC.—$1.0M
1107Multiply Labs—$41M
1108ALPS DX LLC—$900K
1109EPIEN MEDICAL, INC.—$900K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • Ivan PushkarskyExecutive Officer

Patents

USPTO · 0 granted of 5
  • Systems And Methods For Directed Formation Of Size-controlled Multi-cellular Structures And Measurement Of Forces Generated By The Sameapplication
  • Small Molecules To Relax Uterine Smooth Muscle Contractionsapplication
  • Systems And Methods For Directed Formation Of Size-controlled Multi-cellular Structures And Measurement Of Forces Generated By The Sameapplication
  • Small Molecules To Relax Uterine Smooth Muscle Contractionsapplication
  • Systems And Methods For Directed Formation Of Size-controlled Multi-cellular Structures And Measurement Of Forces Generated By The Sameapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.